BMRN
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. insider trading
BioMarin Pharmaceutical Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Novato, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent BMRN insider transactions
3 insiders traded BMRN on the open market between Feb 26, 2026 and Sep 02, 2026 — 5 sales worth $4.3M.
- Bought
- —
- Sold
- $4.3M
- Net
- −$4.3M
- Insiders
- 3
none on a 10b5-1 plan
Davis George Eric
EVP, Chief Legal Officer
−$1.2M
Sep 02, 2026
17,557 sh · $66.28
Friberg Gregory R
EVP, Chief R&D Officer
−$176.7K
May 07, 2026
3,281 sh · $53.85
Guyer Charles Greg
EVP, Chief Technical Officer
−$996.7K
Mar 11, 2026
16,486 sh · $60.46
Friberg Gregory R
EVP, Chief R&D Officer
−$381.9K
Feb 26, 2026
6,326 sh · $60.38
Davis George Eric
EVP, Chief Legal Officer
−$1.6M
Feb 26, 2026
26,061 sh · $61.36
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 02, 2026 | Davis George EricEVP, Chief Legal Officer | 17,557 | $66.28 | −$1.2M |
| May 07, 2026 | Friberg Gregory REVP, Chief R&D Officer | 3,281 | $53.85 | −$176.7K |
| Mar 11, 2026 | Guyer Charles GregEVP, Chief Technical Officer | 16,486 | $60.46 | −$996.7K |
| Feb 26, 2026 | Friberg Gregory REVP, Chief R&D Officer | 6,326 | $60.38 | −$381.9K |
| Feb 26, 2026 | Davis George EricEVP, Chief Legal Officer | 26,061 | $61.36 | −$1.6M |
SEC Form 4 data, Q3 2024 to Q2 2026
BMRN insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 5 insiders traded BMRN on the open market: 0 purchases and 11 sales worth $4.4M, 5 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 4 sales ($3.2M), by 3 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | −$176.7K1 sale | |
| Q1 2026 | — | −$3M3 sales | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | −$123.7K2 sales · all on a plan | |
| Q1 2025 | — | −$685.9K3 sales · 2 on a plan | |
| Q4 2024 | — | −$350.3K1 sale | |
| Q3 2024 | — | −$64.3K1 sale · all on a plan |
- Largest sale
- −$1.6M of BMRN by Davis George Eric (EVP, Chief Legal Officer) on Feb 26, 2026.
Open-market transactions through Jun 30, 2026most recent first
Friberg Gregory R
EVP, Chief R&D Officer
−$382K
Feb 26, 2026
6,326 sh · $60.38
Burkhart Erin10b5-1
GVP, Chief Accounting Officer
−$105.9K
May 20, 2025
1,786 sh · $59.31
Hubbard Cristin10b5-1
EVP, Chief Commercial Officer
−$17.7K
May 02, 2025
273 sh · $64.92
Burkhart Erin10b5-1
GVP, Chief Accounting Officer
−$92.6K
Mar 19, 2025
1,295 sh · $71.52
Guyer Charles Greg
EVP, Chief Technical Officer
−$501.4K
Mar 06, 2025
7,034 sh · $71.28
Burkhart Erin10b5-1
GVP, Chief Accounting Officer
−$91.9K
Feb 24, 2025
1,344 sh · $68.38
Guyer Charles Greg
EVP, Chief Technical Officer
−$350.3K
Nov 12, 2024
5,278 sh · $66.37
Burkhart Erin10b5-1
GVP, Chief Accounting Officer
−$64.3K
Aug 13, 2024
714 sh · $90.00
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 26, 2026 | Friberg Gregory REVP, Chief R&D Officer | 6,326 | $60.38 | −$382K |
| May 20, 2025 | Burkhart Erin10b5-1GVP, Chief Accounting Officer | 1,786 | $59.31 | −$105.9K |
| May 02, 2025 | Hubbard Cristin10b5-1EVP, Chief Commercial Officer | 273 | $64.92 | −$17.7K |
| Mar 19, 2025 | Burkhart Erin10b5-1GVP, Chief Accounting Officer | 1,295 | $71.52 | −$92.6K |
| Mar 06, 2025 | Guyer Charles GregEVP, Chief Technical Officer | 7,034 | $71.28 | −$501.4K |
| Feb 24, 2025 | Burkhart Erin10b5-1GVP, Chief Accounting Officer | 1,344 | $68.38 | −$91.9K |
| Nov 12, 2024 | Guyer Charles GregEVP, Chief Technical Officer | 5,278 | $66.37 | −$350.3K |
| Aug 13, 2024 | Burkhart Erin10b5-1GVP, Chief Accounting Officer | 714 | $90.00 | −$64.3K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
BioMarin Pharmaceutical Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Novato, CA
- Incorporated in
- DE
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001048477
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought BMRN
What the stock actually did in the 90 days following each open-market purchase
Don't check BMRN — let it ping you
Get told the moment an insider moves on BMRN
Pro watches BioMarin Pharmaceutical Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add BMRN to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read BMRN insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are BMRN insiders buying or selling?
- Between Feb 26, 2026 and Sep 02, 2026, 3 BioMarin Pharmaceutical Inc. insiders made no open-market purchases and 5 sales worth $4.3M, a net sale of $4.3M.
- How much BMRN stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 5 BioMarin Pharmaceutical Inc. insiders made no open-market purchases and 11 sales worth $4.4M. 5 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 4 sales ($3.2M). The largest sale was Davis George Eric selling $1.6M on Feb 26, 2026.
- What was the largest recent BMRN insider trade?
- Davis George Eric (EVP, Chief Legal Officer) sold $1.6M of BMRN stock on Feb 26, 2026 at about $61.36 a share.
- When did an insider last buy BMRN shares?
- No open-market purchase by a BioMarin Pharmaceutical Inc. insider appears in the filings from Feb 26, 2026 to Sep 02, 2026 — every recorded open-market transaction in that period was a sale.
- Where does BMRN insider trading data come from?
- From the Form 4 filings BioMarin Pharmaceutical Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.